Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003644 · ClinicalTrials.gov registry record · Phase 3

Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer

A Phase 3 study of Ovarian Cancer, sponsored by Gynecologic Oncology Group.

Completed
Registry status
Phase 3
Development phase
571
Enrollment target
20
Study locations

NCT00003644: Completed Phase 3 study of Ovarian Cancer, sponsored by Gynecologic Oncology Group.

NCT00003644 is a Phase 3 study of Ovarian Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 571 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003644, a Phase 3 study of Ovarian Cancer, has completed, sponsored by Gynecologic Oncology Group.

COMPLETED
Registry status
Phase 3
Development phase
571 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether receiving combined carboplatin and paclitaxel plus continued low-dose paclitaxel is more effective than carboplatin and paclitaxel alone for early-stage ovarian cancer. PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel alone too see how well they work compared to carboplatin and paclitaxel together with continued low-dose paclitaxel in treating patients with early-stage ovarian cancer.

Primary Outcome

The percent of participants with disease recurrence within 5 years

Conditions Studied

Ovarian Cancer

Interventions

  • DRUG carboplatin
  • DRUG paclitaxel

Study Locations (20)

California

  • Alta Bates Comprehensive Cancer Center - Berkeley
  • Peninsula Medical Center - Burlingame
  • Marin Cancer Institute at Marin General Hospital - Greenbrae
  • Sutter Health - Western Division Cancer Research Group - Greenbrae
  • Todd Cancer Institute at Long Beach Memorial Medical Center - Long Beach
  • Kaiser Permanente Medical Center - Los Angeles - Los Angeles
  • Jonsson Comprehensive Cancer Center at UCLA - Los Angeles
  • Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center - Orange
  • University of California Davis Cancer Center - Sacramento
  • California Pacific Medical Center - California Campus - San Francisco
  • Torrance Memorial Medical Center - Torrance

Arizona

  • Banner Thunderbird Medical Center - Glendale
  • Banner Good Samaritan Medical Center - Phoenix
  • CCOP - Western Regional, Arizona - Phoenix

Colorado

  • Colorado Gynecologic Oncology Group P.C. - Aurora
  • North Colorado Medical Center - Greeley
  • McKee Medical Center - Loveland

Arkansas

  • Highlands Oncology Group - Fayetteville - Fayetteville
  • Washington Regional Medical Center - Fayetteville

Alabama

  • University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham

Trial Details

FieldValue
Enrollment Target 571 participants
Start Date 1998-10
Phase Phase 3
Gynecologic Oncology Group

154 total trials

What the finished NCT00003644 record still lists

NCT00003644 is an interventional study that assigns participants to a tested intervention. The registered 571 participants enrollment target is mid-sized for trials with a published cap, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (21% lower).

The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which carboplatin is the first listed.

NCT00003644 names 20 study sites across 5 states, led by California, Arizona, Colorado.

Frequently Asked Questions

What is clinical trial NCT00003644 about?

NCT00003644 is a clinical study titled "Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether receiving combined carboplatin and paclitaxel plus continued low-dose paclitaxel is more effecti...

What is the current status of trial NCT00003644?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 571 participants. The study started on 1998-10.

What conditions does trial NCT00003644 study?

This clinical trial studies the following conditions: Ovarian Cancer.

What interventions are being tested in trial NCT00003644?

The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG).

Who is sponsoring clinical trial NCT00003644?

This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003644 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00003644's enrollment target sits among peer trials

571 40th of 322 higher than 283 of 322 other Ovarian Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04410796 · 571 participants · Phase 2

    Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

  • NCT05131022 · 572 participants · Phase 1

    A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • NCT06346392 · 572 participants · Phase 3

    AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

  • NCT06615050 · 572 participants · Phase 3

    A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00003644, the US trial registry maintained by the National Library of Medicine. NCT00003644 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.